Zmiz1 is a novel regulator of lymphatic endothelial cell gene expression and function
PLOS ONE · 2024
DOI: 10.1371/journal.pone.0302926 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2024. Verfasst von Rajan K C und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cell and Molecular Biology, Tulane University, New Orleans, LA, United States of America. Hauptthemen laut MEDLINE: Cell Proliferation, Endothelial Cells, Homeodomain Proteins, Lymphatic Vessels. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHLBI NIH HHS, NIAID NIH HHS, NINDS NIH HHS.
Abstract (Originalsprache)
Zinc Finger MIZ-Type Containing 1 (Zmiz1), also known as ZIMP10 or RAI17, is a transcription cofactor and member of the Protein Inhibitor of Activated STAT (PIAS) family of proteins. Zmiz1 is critical for a variety of biological processes including vascular development. However, its role in the lymphatic vasculature is unknown. In this study, we utilized human dermal lymphatic endothelial cells (HDLECs) and an inducible, lymphatic endothelial cell (LEC)-specific Zmiz1 knockout mouse model to investigate the role of Zmiz1 in LECs. Transcriptional profiling of ZMIZ1 -deficient HDLECs revealed downregulation of genes crucial for lymphatic vessel development. Additionally, our findings demonstrated that loss of Zmiz1 results in reduced expression of proliferation and migration genes in HDLECs and reduced proliferation and migration in vitro . We also presented evidence that Zmiz1 regulates Prox1 expression in vitro and in vivo by modulating chromatin accessibility at Prox1 regulatory regions. Furthermore, we observed that loss of Zmiz1 in mesenteric lymphatic vessels significantly reduced valve density. Collectively, our results highlight a novel role of Zmiz1 in LECs and as a transcriptional regulator of Prox1, shedding light on a previously unknown regulatory factor in lymphatic vascular biology.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Cell and Molecular Biology, Tulane University, New Orleans, LA, United States of America.
- Molecular Pharmacology and Physiology, Morsani College of Medicine, University of South Florida, Tampa, FL, United States of America.
- Department of Internal Medicine, Division of Hematology-Oncology, Medical School, University of Michigan, Ann Arbor, MI, United States of America.
- Tulane Brain Institute, Tulane University, New Orleans, LA, United States of America.
ORCID-Profile: Rajan K C, Stryder M Meadows
Förderung
- NHLBI NIH HHS
- NIAID NIH HHS
- NINDS NIH HHS
- NHLBI Division of Intramural Research
- Division of Intramural Research, National Institute of Allergy and Infectious Diseases
- National Institute of Neurological Disorders and Stroke
- Priddy Spark Fund -Tulane University
Zitieren
APA
K C, R., Patel, N. R., Shenoy, A., Scallan, J. P., Chiang, M. Y., Galazo, M. J., & Meadows, S. M. (2024). Zmiz1 is a novel regulator of lymphatic endothelial cell gene expression and function. PLOS ONE. https://doi.org/10.1371/journal.pone.0302926
Vancouver
K C R, Patel NR, Shenoy A, Scallan JP, Chiang MY, Galazo MJ, et al. Zmiz1 is a novel regulator of lymphatic endothelial cell gene expression and function. PLOS ONE. 2024. doi:10.1371/journal.pone.0302926
BibTeX
@article{KC2024,
author = {K C, Rajan and Patel, Nehal R and Shenoy, Anoushka and Scallan, Joshua P and Chiang, Mark Y and Galazo, Maria J and Meadows, Stryder M},
title = {Zmiz1 is a novel regulator of lymphatic endothelial cell gene expression and function},
journal = {PLOS ONE},
year = {2024},
doi = {10.1371/journal.pone.0302926}
}
EUVIMED